Christophe Weber, Takeda CEO (Miho Takahashi/The Yomiuri Shimbun via AP Images)
October 27, 2022 11:15 AM EDT
R&D
Pharma

Take­da bumps En­tyvio peak sales, lays out dengue vac­cine plans and celi­ac pipeline in lat­est earn­ings call

Beth Snyder Bulik

Senior Editor

Take­da pro­ject­ed op­ti­mism in Thurs­day’s first-half fis­cal earn­ings call across its port­fo­lio, an­nounc­ing a boost in peak sales es­ti­mates for its al­ready block­buster IBD med …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times